SUNPHARMA's weekly performance was modest, with a 0.47% return, outperforming DRREDDY but underperforming DIVISLAB and HINDUNILVR. The stock's volatility was relatively high at 11.31%, indicating a moderate level of risk. Despite this, SUNPHARMA's Sharpe Ratio of 0.17 suggests that the return was not particularly impressive given the level of risk taken. Overall, SUNPHARMA's performance was middling, with a Max Drawdown of -0.45% indicating some potential for losses.

[Volatility: 11.31%]